Monte Rosa Therapeutics

Monte Rosa Therapeutics received FDA clearance for its Investigational New Drug application for MRT-8102, a NEK7-directed molecular glue degrader targeting inflammatory diseases driven by NLRP3 inflammasome and IL-1β dysregulation.

Monte Rosa Therapeutics presented preclinical data at AACR 2025 showing their CDK2-directed molecular glue degrader MRT-51443 achieved superior tumor regression compared to standard care in HR-positive/HER2-negative breast cancer models.

Roche has signed a $2 billion partnership with Monte Rosa Therapeutics, including a $50 million upfront payment, to develop molecular glue therapies targeting previously "undruggable" proteins in cancer and neurological diseases.

Monte Rosa Therapeutics anticipates Q1 2025 clinical data from its Phase 1 study of MRT-6160, a VAV1-directed molecular glue degrader for immune-mediated conditions.

The NLRP3 protein inhibitors pipeline is robust, with over 20 companies developing more than 25 inhibitors targeting various inflammatory conditions.

Monte Rosa Therapeutics and Novartis have entered an exclusive agreement to develop and commercialize VAV1 molecular glue degraders, including MRT-6160.

Novartis and Monte Rosa Therapeutics have entered into a global agreement to develop and commercialize VAV1 molecular glue degraders, including MRT-6160.

Novartis and Monte Rosa Therapeutics have entered into a global licensing agreement worth up to $2.1 billion to develop VAV1-directed molecular glue degraders.

Monte Rosa Therapeutics and Novartis AG have entered into a collaboration to develop molecular glue degraders (MGDs) targeting VAV1.